Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. (Jaguar Health, Inc.) on July 7, 2015. The report discloses a corporate governance event regarding executive compensation rather than financial performance results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on the authorization of stock options.
Material Changes
On July 7, 2015, the Board of Directors authorized the grant of 113,212 contingent stock options to Lisa A. Conte, the Company's President and Chief Executive Officer. This grant is contingent upon stockholder approval to increase the number of shares authorized under the 2014 Stock Incentive Plan.
Guidance, Outlook, and Management Commentary
The filing details the terms of the Contingent Options:
- Exercise Price: $4.84 per share.
- Vesting Schedule: Monthly vesting over three years, fully vested on the third-year anniversary of the grant authorization date.
- Expiration: Ten years from the grant authorization date.
No forward-looking financial guidance, risk factors, or unusual items were disclosed in this specific report.
Investor Verification Checklist
- Verify whether stockholders have approved the increase in authorized shares under the 2014 Stock Incentive Plan to validate the option grant.
- Confirm the current share price relative to the $4.84 exercise price to assess the intrinsic value of the grant.
- Review the total outstanding share count to understand the potential dilution impact of the 113,212 options.